Roche’s Skyscraper looks on shaky foundations
Roche curbs its TIGIT push, while a co-stimulation crunch could be bad news for Regeneron.
Roche curbs its TIGIT push, while a co-stimulation crunch could be bad news for Regeneron.
ASP3082 grabs some early attention among degraders set to feature at ESMO.
Early attention falls on ADCs originated by ProfoundBio, SystImmune, MediLink and Seagen.
While Roche, Lilly and Merck push on aggressively, Novartis throws in the towel.
The group reaffirms pancreatic cancer promise with RMC-6236, but has it found the best dose?
After Tacti-003’s controlled cohorts fail, Immutep plays up single-arm data in PD-L1 non-expressers.